Standard BioTools Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Dr. Egholm; Other NEO average total compensation $2.85M.
- 2024-12-31: PEO Dr. Egholm; Other NEO average total compensation $2.72M.
- 2023-12-31: PEO Dr. Egholm; Other NEO average total compensation $1.23M.
- 2022-12-31: PEO Dr. Egholm; Other NEO average total compensation $3.63M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Dr. Egholm | $2.85M | $1.92M | $21.33 | $124.75 | -$74.90M | total revenue $186.58M | 2026-04-27 | ||
| 2024-12-31 | Dr. Egholm | $2.72M | $1.55M | $29.17 | $93.49 | -$138.88M | $174.43M | 2026-04-27 | ||
| 2023-12-31 | Dr. Egholm | $1.23M | $1.97M | $36.83 | $94.03 | -$74.66M | $106.34M | 2026-04-27 | ||
| 2022-12-31 | Dr. Egholm | $3.63M | $1.33M | $19.50 | $89.90 | -$190.10M | $97.95M | 2026-04-27 | ||
| 2021-12-31 | Mr. Linthwaite | $2.15M | $1.77M | $65.33 | $100.02 | -$59.24M | $130.58M | 2026-04-27 | ||
| 2024-12-31 | Dr. Egholm | $2.72M | $1.55M | $29.17 | $93.49 | -$138.88M | total revenue $174.43M | 2025-04-30 | ||
| 2023-12-31 | Dr. Egholm | $1.23M | $1.97M | $36.83 | $94.03 | -$74.66M | $106.34M | 2025-04-30 | ||
| 2022-12-31 | Dr. Egholm | $3.63M | $1.33M | $19.50 | $89.90 | -$190.10M | $97.95M | 2025-04-30 | ||
| 2021-12-31 | Mr. Linthwaite | $2.15M | $1.77M | $63.33 | $100.02 | -$59.24M | $130.58M | 2025-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |